News

Prothena is advancing its early‑to‑mid‑stage pipeline of programs with Bristol Myers, including BMS‑986446 for Alzheimer's Disease and PRX019, a potential treatment for neurodegenerative diseases. The company has completed a phase I study evaluating the safety and pharmacokinetics of single‑dosing administration of PRX019.

Full article

Roche's prasinezumab for early-stage Parkinson's disease also continues to generate encouraging long‑term clinical evidence. This asset has peak sales potential exceeding $3.5 billion, and Prothena retains an option to co‑promote it in the United States.

Full article

The company's pipeline progress has been driven by partnered assets, such as coramitug for ATTR amyloidosis with cardiomyopathy (ATTR-CM) in the phase III CLEOPATTRA program. Novo Nordisk is evaluating this asset, which was initially developed by Prothena and acquired by Novo Nordisk in July 2021. The company received a $50 million clinical milesto...

Full article

PRTA's shares have gained around 11% over the past six months, outperforming its industry with a 5.1% growth. This rally can be attributed to growing investor confidence in Prothena's late-stage partnered programs and milestone payments from strategic partners.

Full article

Investor sentiment reflects concerns over the company’s longer‑term metrics. Revenues have grown at an estimated 5.5% compounded annual growth rate over the past five years, below the sector average. Return on equity stands at 8.4% versus an industry average of roughly 10%. Net debt to EBITDA is 12.9×, suggesting high leverage that could limit cred...

Full article

Nelnet Campus Commerce has entered a strategic partnership with Atrium Campus, a cloud‑native campus card and mobile credential provider. The collaboration is intended to replace legacy campus‑card systems, lower costs, and enhance operational efficiency for higher‑education institutions. Nelnet Campus Commerce already serves more than 1,100 school...

Full article

Nelnet (NYSE:NNI) reported Q1 revenue down 7.1% year‑on‑year and missed analysts by 20.4%. Net interest income and EPS estimates were also significantly below expectations, and NNI shares fell 6.1% since the earnings release. The company’s CEO said all business segments were operating at a high level, but the weak quarterly performance made Nelnet...

Full article

Overall, PG&E’s strong earnings outlook, significant methane cuts, and attractive valuation fundamentals are balanced by exposure to wildfire liability risks and potential regulatory constraints that could affect future cost recovery and rate‑base growth.

Full article

Projected financials through 2029 anticipate revenue of $28.5 billion and earnings of $4.3 billion, underpinning the fair‑value estimate of $22.59. These figures depend on continued grid modernization and wildfire‑mitigation spending, while regulatory risks—especially wildfire liability reforms and cost‑recovery caps—remain pivotal. PG&E’s corporat...

Full article

Valuation metrics paint PCG as undervalued relative to earnings. The stock trades at 13.2x P/E, below the industry average of 22.3x and the peer average of 53.7x, while a tailored fair P/E of 24.2x suggests upside. Other indicators—forward P/E 10.42 versus PORK’s 15.49, PEG 0.66 versus 2.20, and P/B 1.44 versus 1.48—position PG&E as a superior valu...

Full article